Clinical Trials Logo

Neoplasm, Esophageal clinical trials

View clinical trials related to Neoplasm, Esophageal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04595149 Recruiting - Clinical trials for Neoplasm, Esophageal

Tapestry: Addition of TGF-β and PDL-1 Inhibition to Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma

TAPESTRY
Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

The outcome of irresectable oesophaguscancer is poor, despite the fact that curative treatment with definitive chemoradiation is possible. The outcome of treatment can possibly be improved by combining chemoradiation with immunotherapy such as bintrafusp alfa, a combined TGF-β and PD-L1 inhibitor. In this study investigators investigate the feasibility of combining bintrafusp alfa with definitive chemoradiation in patients with irresectable squamous cell carcinoma of the esophagus.

NCT ID: NCT03791905 Recruiting - Clinical trials for Squamous Cell Carcinoma

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT02530983 Recruiting - Esophageal Cancer Clinical Trials

Mayo Clinic Upper Digestive Disease Survey

UDD
Start date: August 2015
Phase:
Study type: Observational

The Mayo Clinic Conduit Report Card Questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires/survey. Data will also lead to the establishment of "normal" or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.